Actinium Pharmaceuticals has established a Scientific Advisory Board with five leading experts in oncology and radiopharmaceuticals to guide the development of its targeted radiotherapy treatments, including ATNM-400 for metastatic prostate cancer. This board will support clinical strategies, trial design, and molecular imaging to enhance Actinium's pipeline across solid tumors and blood cancers. The move aims to accelerate the development of innovative cancer therapies addressing significant unmet medical needs. The company continues to advance multiple programs, including ATNM-400 in Phase 1 trials and Actimab-A for leukemia, backed by extensive patent holdings and collaborations.
Actinium Pharmaceuticals' formation of a Scientific Advisory Board provides context for readers interested in health sector developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health stocks, 121 rose and 18 fell. Notable movers include ROIV at USD 40.25 with a 1-day change of +3.52%, NUWE at USD 4.72 with +3.06%, and CTXR at USD 0.54 with -2.98%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
